NASDAQ · Biotechnology · USD
CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Analysis
CAMP4 THERAPEUTICS CORPORATION (CAMP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CAMP Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.17
- Previous Close
- $3.16
- Day's Range
- 2.96–3.33
- 52-Week Range
- 2.86–7.75
- Volume
- 186.41K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.26
Valuation
- Market Cap
- $215.24M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 51.05
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.32
Financials (FY)
- Revenue (FY)
- $3.50M+436.50%
- Net Income (FY)
- −$80.40M
- Shares Outstanding
- 62.75M
- 1-Year Return
- −3.52%
Dividend and dates
- Avg Volume
- 273.76K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CAMP closed at $3.29, −3.52% over 1 year.
CAMP4 THERAPEUTICS CORPORATION (CAMP) has a market capitalization of $215.24M.
In fiscal 2025, CAMP reported revenue of $3.50M.
CAMP Stock Return by Calendar Year
CAMP4 THERAPEUTICS CORPORATION (CAMP) return since Oct 2024: what $10,000 became
- 1 year
- $10,000 $9,648
- −3.52%
- Since Oct 2024
- $10,000 $3,069
- −69.31%
If you had invested $10,000 in CAMP4 THERAPEUTICS CORPORATION (CAMP) at the close on October 11, 2024, the earliest close on record here, it would have been worth $3,069 at the close on October 21, 2026: −69.31% in total, −44.18% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −46.33% |
| 2025 | +17.43% |
| 2024 (partial year) | −51.31% |
As of October 21, 2026.
CAMP Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $3.50M | −$80.40M | −2,298.5% |
| 2024 | $652.00K | −$51.79M | −7,943.4% |
| 2023 | $350.00K | −$49.29M | −14,083.1% |
| 2022 | $0.00 | −$44.19M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $3.50M | — | −$52.06M | −$80.40M | −2,298.5% |
| 2024 | $652.00K | — | −$53.09M | −$51.79M | −7,943.4% |
| 2023 | $350.00K | — | −$51.88M | −$49.29M | −14,083.1% |
| 2022 | $0.00 | — | −$45.00M | −$44.19M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
CAMP Valuation vs Biotechnology Median
Median of 608 stocks| Metric | CAMP | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 51.05 | 13.30 | 3.8x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8
BenzingaCAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
YahooChardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
BenzingaCamp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
SeekingAlphaCAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
MarketBeatCamp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow
SeekingAlpha
All 17 articles ↓Show fewer ↑
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
YahooCAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder
BenzingaCAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
YahooCAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder
BenzingaCAMP4 to Participate in Upcoming Investor Conferences
YahooPiper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15
BenzingaCAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
YahooCAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
YahooCamp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate
BenzingaCAMP4 Moves Into Human Trials -- The Upside Is Underpriced
SeekingAlphaCAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B